Which has stronger earnings and valuation, AVBP or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is AVBP or BLTE more profitable?

Belite Bio's return on equity of -13.14% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -48.98% -45.44% Belite Bio N/A -13.14% -12.88%

Which has preferable valuation & earnings, SRRK or AVBP?

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is SRRK or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% ArriVent BioPharma N/A -48.98% -45.44%

Does the media prefer SRRK or AVBP?

In the previous week, Scholar Rock had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for Scholar Rock and 2 mentions for ArriVent BioPharma. Scholar Rock's average media sentiment score of 0.77 beat ArriVent BioPharma's score of 0.46 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CGON or AVBP more profitable?

CG Oncology's return on equity of -23.33% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% ArriVent BioPharma N/A -48.98% -45.44%

Does the media prefer CGON or AVBP?

In the previous week, CG Oncology had 10 more articles in the media than ArriVent BioPharma. MarketBeat recorded 12 mentions for CG Oncology and 2 mentions for ArriVent BioPharma. CG Oncology's average media sentiment score of 0.88 beat ArriVent BioPharma's score of 0.46 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LEGN or AVBP?

In the previous week, Legend Biotech and Legend Biotech both had 2 articles in the media. ArriVent BioPharma's average media sentiment score of 0.46 beat Legend Biotech's score of -0.07 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TWST or AVBP?

In the previous week, Twist Bioscience had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 5 mentions for Twist Bioscience and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.46 beat Twist Bioscience's score of 0.36 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ArriVent BioPharma (AVBP) Competitors

$34.67 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$34.62 -0.05 (-0.13%)

As of 07/2/2026 04:10 PM Eastern

Compare

AVBP vs. BLTE, SRRK, CGON, LEGN, and TWST

Should you buy ArriVent BioPharma stock or one of its competitors? MarketBeat compares ArriVent BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ArriVent BioPharma include Belite Bio (BLTE), Scholar Rock (SRRK), CG Oncology (CGON), Legend Biotech (LEGN), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

How does ArriVent BioPharma compare to Belite Bio?

ArriVent BioPharma (NASDAQ:AVBP) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Belite Bio's return on equity of -13.14% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Belite Bio	N/A	-13.14%	-12.88%

ArriVent BioPharma has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its share price is 223% less volatile than the broader market.

ArriVent BioPharma presently has a consensus target price of $43.14, suggesting a potential upside of 24.44%. Belite Bio has a consensus target price of $203.00, suggesting a potential upside of 38.44%. Given Belite Bio's higher possible upside, analysts clearly believe Belite Bio is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, ArriVent BioPharma had 2 more articles in the media than Belite Bio. MarketBeat recorded 2 mentions for ArriVent BioPharma and 0 mentions for Belite Bio. ArriVent BioPharma's average media sentiment score of 0.46 beat Belite Bio's score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ArriVent BioPharma	Neutral
Belite Bio	Neutral

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Belite Bio is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Summary

ArriVent BioPharma beats Belite Bio on 8 of the 14 factors compared between the two stocks.

How does ArriVent BioPharma compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Scholar Rock has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

ArriVent BioPharma's return on equity of -48.98% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Scholar Rock presently has a consensus target price of $56.00, indicating a potential upside of 2.04%. ArriVent BioPharma has a consensus target price of $43.14, indicating a potential upside of 24.44%. Given ArriVent BioPharma's higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Scholar Rock had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for Scholar Rock and 2 mentions for ArriVent BioPharma. Scholar Rock's average media sentiment score of 0.77 beat ArriVent BioPharma's score of 0.46 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Scholar Rock and ArriVent BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does ArriVent BioPharma compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

CG Oncology presently has a consensus price target of $81.73, suggesting a potential upside of 16.16%. ArriVent BioPharma has a consensus price target of $43.14, suggesting a potential upside of 24.44%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

CG Oncology's return on equity of -23.33% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
ArriVent BioPharma	N/A	-48.98%	-45.44%

In the previous week, CG Oncology had 10 more articles in the media than ArriVent BioPharma. MarketBeat recorded 12 mentions for CG Oncology and 2 mentions for ArriVent BioPharma. CG Oncology's average media sentiment score of 0.88 beat ArriVent BioPharma's score of 0.46 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CG Oncology has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

CG Oncology has higher revenue and earnings than ArriVent BioPharma. CG Oncology is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$5.07M	1,223.80	-$160.99M	-$2.33	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CG Oncology beats ArriVent BioPharma on 9 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

ArriVent BioPharma has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.14B	4.88	-$296.80M	-$0.68	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

ArriVent BioPharma has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Legend Biotech has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

In the previous week, Legend Biotech and Legend Biotech both had 2 articles in the media. ArriVent BioPharma's average media sentiment score of 0.46 beat Legend Biotech's score of -0.07 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Legend Biotech currently has a consensus target price of $60.23, suggesting a potential upside of 101.37%. ArriVent BioPharma has a consensus target price of $43.14, suggesting a potential upside of 24.44%. Given Legend Biotech's higher probable upside, equities analysts clearly believe Legend Biotech is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

ArriVent BioPharma beats Legend Biotech on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, Twist Bioscience had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 5 mentions for Twist Bioscience and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.46 beat Twist Bioscience's score of 0.36 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Twist Bioscience has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

9.5% of ArriVent BioPharma shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Twist Bioscience has higher revenue and earnings than ArriVent BioPharma. Twist Bioscience is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	16.41	-$77.67M	-$1.33	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

ArriVent BioPharma has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Twist Bioscience currently has a consensus target price of $79.30, suggesting a potential downside of 20.09%. ArriVent BioPharma has a consensus target price of $43.14, suggesting a potential upside of 24.44%. Given ArriVent BioPharma's higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Twist Bioscience beats ArriVent BioPharma on 8 of the 15 factors compared between the two stocks.

Get ArriVent BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVBP vs. The Competition

Export

Metric	ArriVent BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.61B	$3.73B	$6.96B	$12.41B
Dividend Yield	N/A	2.22%	2.68%	6.63%
P/E Ratio	-9.99	21.80	27.81	24.72
Price / Sales	N/A	319.21	554.07	111.02
Price / Cash	N/A	143.20	48.59	58.15
Price / Book	4.66	8.66	10.96	6.45
Net Income	-$166.31M	$23.81M	$3.57B	$337.01M
7 Day Performance	1.97%	3.45%	2.18%	1.36%
1 Month Performance	16.42%	8.51%	4.54%	1.68%
1 Year Performance	67.04%	62.61%	33.33%	23.97%

ArriVent BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVBP ArriVent BioPharma	2.0785 of 5 stars	$34.67 flat	$43.14 +24.4%	+64.3%	$1.61B	N/A	N/A	40
BLTE Belite Bio	2.8238 of 5 stars	$145.09 -1.3%	$203.00 +39.9%	+158.1%	$5.90B	N/A	N/A	10
SRRK Scholar Rock	1.5972 of 5 stars	$51.27 +4.2%	$56.00 +9.2%	+54.4%	$5.89B	N/A	N/A	140	Positive News
CGON CG Oncology	3.4185 of 5 stars	$65.73 -0.8%	$81.73 +24.3%	+163.7%	$5.84B	$5.07M	N/A	61	News Coverage Positive News Gap Down
LEGN Legend Biotech	2.907 of 5 stars	$29.30 -0.1%	$60.23 +105.6%	-16.7%	$5.45B	$1.14B	N/A	2,965

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVBP) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ArriVent BioPharma (AVBP) Competitors

AVBP vs. BLTE, SRRK, CGON, LEGN, and TWST

How does ArriVent BioPharma compare to Belite Bio?

Summary

How does ArriVent BioPharma compare to Scholar Rock?

Summary

How does ArriVent BioPharma compare to CG Oncology?

Summary

How does ArriVent BioPharma compare to Legend Biotech?

Summary

How does ArriVent BioPharma compare to Twist Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ArriVent BioPharma (AVBP) Competitors

AVBP vs. BLTE, SRRK, CGON, LEGN, and TWST

How does ArriVent BioPharma compare to Belite Bio?

Is AVBP or BLTE more profitable?

Which has more volatility & risk, AVBP or BLTE?

Do analysts prefer AVBP or BLTE?

Does the media favor AVBP or BLTE?

Do insiders & institutionals hold more shares of AVBP or BLTE?

Which has stronger earnings and valuation, AVBP or BLTE?

Summary

How does ArriVent BioPharma compare to Scholar Rock?

Which has more volatility and risk, SRRK or AVBP?

Which has preferable valuation & earnings, SRRK or AVBP?

Is SRRK or AVBP more profitable?

Do analysts recommend SRRK or AVBP?

Do institutionals and insiders have more ownership in SRRK or AVBP?

Does the media prefer SRRK or AVBP?

Summary

How does ArriVent BioPharma compare to CG Oncology?

Do analysts recommend CGON or AVBP?

Is CGON or AVBP more profitable?

Does the media prefer CGON or AVBP?

Which has more volatility & risk, CGON or AVBP?

Which has better valuation & earnings, CGON or AVBP?

Do institutionals & insiders hold more shares of CGON or AVBP?

Summary

How does ArriVent BioPharma compare to Legend Biotech?

Which has better earnings & valuation, LEGN or AVBP?

Is LEGN or AVBP more profitable?

Which has more risk & volatility, LEGN or AVBP?

Does the media prefer LEGN or AVBP?

Do analysts rate LEGN or AVBP?

Do institutionals and insiders hold more shares of LEGN or AVBP?

Summary

How does ArriVent BioPharma compare to Twist Bioscience?

Does the media refer more to TWST or AVBP?

Which has more risk & volatility, TWST or AVBP?

Do institutionals & insiders hold more shares of TWST or AVBP?

Which has higher earnings and valuation, TWST or AVBP?

Is TWST or AVBP more profitable?

Do analysts prefer TWST or AVBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools